A study of patients with HER2-positive breast cancer (APHINITY)

A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer (APHINITY)

  • Cancer
  • Breast Cancer
  • Breast Cancer HER-2 Positive
Please note that the recruitment status of the trial at your site may differ from the overall study status because some study sites may recruit earlier than others.
Trial Status:


This trial runs in
  • Basel
Trial Identifier:

NCT01358877 2010-022902-41 (EudraCT number)

      Show trial locations

      The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical trial see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.

      The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

      Results Disclaimer

      Trial Summary

      This randomized, double-blind, placebo-controlled, two-arm study will assess the safety and efficacy of pertuzumab in addition to chemotherapy plus trastuzumab as adjuvant therapy in participants with operable HER2-positive primary breast cancer. This study will be carried out in collaboration with the Breast International Group (BIG).

      F. Hoffmann-La Roche Ltd Sponsor
      Phase III Phase
      NCT01358877,2010-022902-41 (EudraCT number) Trial Identifier
      RO4368451 Treatments
      Breast Cancer Condition
      Official Title

      A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer (APHINITY)

      Eligibility Criteria

      All Gender
      18 Years and older Age
      No Healthy Volunteers
      Inclusion Criteria
      • Non-metastatic operable primary invasive HER2-positive carcinoma of the breast that is histologically confirmed, and adequately excised
      • Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to (</=) 1
      • Known hormone receptor status (estrogen receptor and progesterone receptor)
      • The interval between definitive surgery for breast cancer and the first dose of chemotherapy must be no more than 8 weeks (56 days). The first cycle of chemotherapy must be administered within 7 days of randomization or on Day 56, whichever occurs first
      • Baseline left ventricular ejection fraction (LVEF) greater than or equal to (>/=) 55 percent (%) measured by echocardiogram (ECHO) or Multiple-Gated Acquisition (MUGA) Scan
      • Confirmed HER2 positive status
      • Completion of all necessary baseline laboratory and radiologic investigations prior to randomization
      • Women of childbearing potential and male participants with partners of childbearing potential must agree to use effective contraception (as defined by the protocol) by the participant and/or partner for the duration of the study treatment and for at least 7 months after the last dose of study drug
      Exclusion Criteria
      • History of any prior (ipsi- and/or contralateral) invasive breast cancer
      • History of non-breast malignancies within the 5 years prior to study entry, except for carcinoma in situ of the cervix, carcinoma in situ of the colon, melanoma in situ, and basal cell and squamous cell carcinomas of the skin
      • Any "clinical" T4 tumor as defined by primary tumor/regional lymph nodes/distant metastasis (TNM), including inflammatory breast cancer
      • Any node-negative tumor
      • Any previous systemic chemotherapy for cancer or radiotherapy for cancer
      • Prior use of anti-HER2 therapy for any reason or other prior biologic or immunotherapy for cancer
      • Concurrent anti-cancer treatment in another investigational trial
      • Serious cardiac or cardiovascular disease or condition
      • Other concurrent serious diseases that may interfere with planned treatment including severe pulmonary conditions/illness
      • Abnormal laboratory tests immediately prior to randomization
      • Pregnant or lactating women
      • Sensitivity to any of the study medications or any of the ingredients or excipients of these medications

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now